Arginase inhibition mediates cardioprotection during ischaemia-reperfusion

Cardiovascular Research

Volumn 85, Issue 1, 2010, Pages 147-154

  Jung, Christian ^a   Gonon, Adrian T ^a   Sjöquist, Per Ove ^a   Lundberg, Jon O ^b   Pernow, John ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Arginase; Cardioprotection; Ischaemia reperfusion; Nitric oxide; Nor NOHA

Indexed keywords

ARGINASE; CITRULLINE; N(G) HYDROXYARGININE; N(G) METHYLARGININE; NITRIC OXIDE; NITRITE; ORNITHINE;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY;

AMINO ACIDS; ANIMALS; ARGINASE; ARGININE; BLOOD PRESSURE; ENZYME INHIBITORS; HEART RATE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 72049107764     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp303     Document Type: Article

References (35)

1. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905-1912.
2. Cohen MV, Yang XM, Downey JM. Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Car-diovasc Res 2006;70:231-239.
3. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007;34:906-911.
4. Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA. Insulin reduces plasma argi-nase activity in type 2 diabetic patients. Diabetes Care 2008;31:134-139.
5. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008;102:923-932.
6. Vanhoutte PM. Arginine and arginase: endothelial NO synthase double crossed? Circ Res 2008;102:866-868.
7. Bachetti T, Comini L, Francolini G, Bastianon D, Valetti B, Cadei M et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 2004;37:515-523.
8. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 2003;17:2328-2330.
9. Moali C, Boucher JL, Sari MA, Stuehr DJ, Mansuy D. Substrate specificity of NO synthases: detailed comparison of L-arginine, homo-L-arginine, their N omega-hydroxy derivatives, and N omega-hydroxynor-L-arginine. Biochemistry 1998;37: 10453-10460.
10. Jeyabalan G, Klune JR, Nakao A, Martik N, Wu G, Tsung A et al. Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. Nitric Oxide 2008;19:29-35.
11. Jung KH, Chu K, Ko SY, Lee ST, Sinn DI, Park DK et al. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. Stroke 2006;37:2744-2750.
12. Lu HR, Remeysen P, De Clerck F. Does the antiarrhythmic effect of ischemic preconditioning in rats involve the L-arginine nitric oxide pathway? J Cardiovasc Pharmacol 1995;25:524-530.
13. Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 1993;110:1457-1464. (Pubitemid 23360978)
14. Bulhak A, Roy J, Hedin U, Sjoquist PO, Pernow J. Cardioprotective effect of rosu-vastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Am J Physiol Heart Circ Physiol 2007;292: H3158-H3163.
15. Govoni M, Jansson EA, Weitzberg E, Lundberg JO. The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. Nitric Oxide 2008;19:333-337.
16. Lindroth P, Mopper K. High performance liquid chromatographic determination of subpicomole amounts of amino acids by precolumn fluorescence derivatization with O-phthaldialdehyde. Anal Chem 1979;51:1667-1674.
17. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006;40:16-23.
18. Wykes V, Garthwaite J. Membrane-association and the sensitivity of guanylyl cyclase-coupled receptors to nitric oxide. Br J Pharmacol 2004;141:1087-1090.
19. Gonon AT, Erbas D, Broijersen A, Valen G, Pernow J. Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2004;286:H1767-H1774.
20. Gonon AT, Gourine AV, Pernow J. Cardioprotection from ischemia and reperfu-sion injury by an endothelin A-receptor antagonist in relation to nitric oxide production. J Cardiovasc Pharmacol 2000;36:405-412.
21. Bulhak AA, Sjoquist PO, Xu CB, Edvinsson L, Pernow J. Protection against myo-cardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1. Basic Res Cardiol 2006;101:244-252.
22. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1-17.
23. Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher JL. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide 1999;3:427-438.
24. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001;280:E75-E82.
25. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008;102:95-102.
26. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008;7:156-167.
27. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol 2005;25:915-922.
28. Gladwin MT, Schechter AN, Kim-Shapiro DB, Patel RP, Hogg N, Shiva S et al. The emerging biology of the nitrite anion. Nat Chem Biol 2005;1:308-314.
29. Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W et al. Cyto-protective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest 2005;115:1232-1240.
30. Gonzalez FM, Shiva S, Vincent PS, Ringwood LA, Hsu LY, Hon YY et al. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation 2008;117: 2986-2994.
31. Elrod JW, Calvert JW, Gundewar S, Bryan NS, Lefer DJ. Nitric oxide promotes distant organ protection: evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci USA 2008;105:11430-11435.
32. Sodha NR, Boodhwani M, Clements RT, Feng J, Xu SH, Sellke FW. Coronary microvascular dysfunction in the setting of chronic ischemia is independent of arginase activity. Microvasc Res 2008;75:238-246.
33. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 2009;157:922-930.
34. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA et al. Adiponectin cardiopro-tection after myocardial ischemia/reperfusion involves the reduction of oxidative/ nitrative stress. Circulation 2007;115:1408-1416.
35. Jones SP, Girod WG, Huang PL, Lefer DJ. Myocardial reperfusion injury in neur-onal nitric oxide synthase deficient mice. Coron Artery Dis 2000;11:593-597.